texas oncology more breakthroughs. more victories

Share:

 
 

Carlos Becerra, M.D.

Education

Universidad del Valle; Fellowship: UT Southwestern Medical Center Hematology and Medical Oncology; Residency: Saint Francis Hospital Chief Resident Internal Medicine 1993-1994, PG-2 and PG-3 1992-1994, PG-1 Internal Medicine 1991-1992.

Why a patient should choose treatment at your practice?

We provide comprehensive care to our patients using a multi-disciplinary approach. We also offer unique clinical trials and believe in the importance of support systems. 

What is your personal philosophy around patient care?

Personal, holistic approach.

Publications

Show all Publications
  • Phase 1 Study of MRX34, a Liposomal miR-34a Mimic, in Patients With Advanced Solid Tumours

    British Journal of Cancer, 2020

  • Phase I Dose-Escalation Trial of the Oral AKT Inhibitor Uprosertib in Combination With the Oral MEK1/MEK2 Inhibitor Trametinib in Patients With Solid Tumors

    Cancer Chemotherapy and Pharmacology, 2020

  • A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of Taselisib (GDC-0032) in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced, or Metastatic Breast Cancer

    Breast Cancer Research and  Treatment, 2019

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    The New England Journal of Medicine, 2019

  • Open-Label Study To Evaluate Trifluridine/Tipiracil Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumours and Hepatic Impairment

    British Journal of Clinical Pharmacology, 2019

  • Targeting LIF-Mediated Paracrine Interaction for Pancreatic Cancer Therapy and Monitoring

    Nature, 2019

  • Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

    Clinical Cancer Research, 2018

  • Locally Advanced Carcinosarcoma of the Pancreas

    Proceedings (Baylor University. Medical Center), 2018

  • Pembrolizumab Versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-oesophageal Junction Cancer (KEYNOTE-061): a Randomised, Open-label, Controlled, Phase 3 Trial

    The Lancet, 2018

  • Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

    Clinical Cancer Research, 2018

  • Extended Dosing With CC-486 (Oral Azacitidine) in Patients With Myeloid Malignancies

    American Journal of Hematology, 2018

  • Phase 1/1b Dose Escalation and Expansion Study of BEZ235, a Dual PI3K/mTOR Inhibitor, in Patients With Advanced Solid Tumors Including Patients With Advanced Breast Cancer

    Cancer Chemotherapy and Pharmacology, 2018

  • Genome-Wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

    Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2018

  • A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil

    Journal of Clinical Pharmacology, 2017

  • Effect of Everolimus on the Pharmacokinetics of Octreotide Long-Acting Repeatable in Patients With Advanced Neuroendocrine Tumors: An Analysis of the Randomized Phase III RADIANT-2 Trial

    Clinical Pharmacology and Therapeutics, 2017

  • Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

    Clinical Therapeutics, 2016

  • A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in patients with Advanced Cancer

    Clinical Cancer Research, 2016

  • A Phase I Clinical Trial of ASG-5ME, a Novel Drug-antibody Conjugate Targeting SLC44A4, in Patients with Advanced Pancreatic and Gastric Cancers

    Investigational New Drugs, 2016

  • Randomized Phase 1 Crossover Study Assessing the Bioequivalence of Capsule and tTablet formulations of Dovitinib (TKI258) in Patients with Advanced Solid Tumors

    Cancer Chemotherapy and Pharmacology, 2016

  • Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

    Oncology, 2016

  • A Phase I Trial of Panobinostat (LBH589) in Patients with Metastatic Melanoma

    Cancer Medicine, 2016

  • An Innovative, Multi-arm, Complete Phase 1b Study of the Novel Anti-cancer Agent Tasisulam in Patients with Advanced Solid Tumors

    Investigational New Drugs, 2015

  • Phase I Study of the MEK Inhibitor Trametinib in Combination with the AKT Inhibitor Afuresertib in Patients with Solid Tumors and Multiple Myeloma

    Cancer Chemotherapy and Pharmacology, 2015

  • Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KHL Conjugate Vaccines for Follicular Lymphoma

    BioMed Research International, 2015

  • Figitumumab in Patients with Refractory Metastatic Colorectal Cancer Previously Treated with Standard Therapies: a Nonrandomized, Open-label, Phase II Trial

    Cancer Chemotherapy and Pharmacology, 2014

  • A Phase I Dose-escalation Study of MEDI-575, a PDGFRα Monoclonal Antibody, in Adults with Advanced Solid Tumors

    Cancer Chemotherapy and Pharmacology, 2014

  • Phase 2 Trial of Afatinib, an ErbB Family Blocker, in Solid Tumors Genetically Screened for Target Activation

    Cancer, 2013

  • A Phase II Study with Cetuximab and Radiation Therapy with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92

    Journal of Thoracic Oncology, 2013

  • Safety. Pharmacokinetic, Pharmacodynamic, and Efficacy Data for the Oral MEK Inhibitor Trametinib: a Phase I Dose-escalation Trial

    Lancet Oncology, 2012

  • Gemcitabine Plus Enzaustarin or Single-agent Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: Results of a Phase II, Randomized, Noncomparative Study

    Investigational New Drugs, 2011

  • Referral Patterns and Adjuvant Chemotherapy use in Patients With Stage II Colon Cancer

    Clinical Colorectal Cancer, 2011

  • Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

    Clinical Cancer Research, 2010

  • Phase I Dose Escalation Study with Irinotecan, Capecitabine, Epirubicin, and Granulocyte Colony-stimulating Factor Support for Patients with Solid Malignancies

    American Journal of Clinical Oncology, 2008

  • The Continuum of Care: a Paradigm for the Management of Metastatic Colorectal Cancer

    Oncologist, 2007

  • Adverse Effects of Bevacizumab and Their Management in Solid Tumors

    Supportive Cancer Therapy, 2006

  • Efficacy of Sequential Treatment of HCT116 Colon Cancer Monolayers and Aenografts with Docetaxel, Flavopiridol, and 5-fluorouracil

    Acta Pharmacologica Sinica, 2006

  • A Phase II Clinical and Pharmacokinetic Study of Intravenous Exatecan Mesylate (DX-8951f) in Patients with Untreated Metastasis Gastric Cancer

    Investigational New Drugs, 2005

  • Dissecting Role of Regulatory Factors in NF-kB Pathway with siRNA

    Acta Pharmacologica Sinica, 2005

  • Selective Identification of Secreted and Transmembrane Breast Cancer Markers using Escherichia Coli Ampicillin Secretion Trap

    Cancer Research, 2005

  • A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers

    American Journal of Clinical Oncology, 2005

  • IҝB Kinase α(IKKα) Regulates Sub-cellular Distribution and Turnover of Cyclin D1 by Phosphorylation

    Journal of Biological Chemistry, 2005

  • Enhanced Chemosensitivity to Irinotecan by RNA Interference Mediated Down-regulation of the NF-kB p65 Subunit

    Clinical Cancer Research, 2004

  • Irinotecan, Epirubicin, and Capecitabine in Metastatic Adenocarcinomas: Preliminary Results of a Phase I Study

    Oncology (Williston Park), 2004

  • Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference

    Clinical Cancer Research, 2003

  • Small Interfering RNAs Directed Against B-Catenin Inhibit the In-vitro and In-vivo Growth of Colon Cancer Cells

    Clinical Cancer Research, 2003

  • Increased Toxicity and Lack of Efficacy of Rofecoxib in Combination with Chemotherapy for Treatment of Metastatic Colorectal Cancer: A Phase II Study

    International Journal of Cancer, 2003

  • Phase II Study of Pemetrexed Disodium (Alimta(R)) Administered with Oral Folic Acid in Patients with Advanced Gastric Cancer

    Annals of Oncology, 2003

  • Reversible Renal Toxicity Resulting From high single Doses of the New Radiosensitizer Gadolinium Texaphyrin

    American Journal of Clinical Oncology, 2000

  • A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

    Clinical Cancer Research, 1999

  • Palmitoyl-Protein Thioesterase Deficiency in a Novel Granular Variant of Late Infantile Neuronal Ceroid Lipofuscinosis

    Pediatric Neurology, 1998

  • Mutations in the Palmitoyl Protein Thioesterase Gene (PPT;CLN1) Causing Juvenile Neuronal Ceroid Lipofuscinosis with Granular Osmiophilic Deposits

    Human Molecular Genetics, 1998

  • Molecular Genetics of Palmitoyl Protein Thioesterase Deficiency in the U.S.

    Journal of Clinical Investigation, 1998

Accolades & Memberships

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • Colombian Medical Association